MYOVIEW 30ML Drug Patent Profile
✉ Email this page to a colleague
When do Myoview 30ml patents expire, and what generic alternatives are available?
Myoview 30ml is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.
This drug has eight patent family members in seven countries.
The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.
DrugPatentWatch® Generic Entry Outlook for Myoview 30ml
Myoview 30ml was eligible for patent challenges on February 9, 2000.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MYOVIEW 30ML
| International Patents: | 8 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MYOVIEW 30ML at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for MYOVIEW 30ML
Generic Entry Date for MYOVIEW 30ML*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MYOVIEW 30ML
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Astellas Pharma Inc | Phase 2 |
| GE Healthcare | Phase 4 |
US Patents and Regulatory Information for MYOVIEW 30ML
MYOVIEW 30ML is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MYOVIEW 30ML is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MYOVIEW 30ML
Radiopharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | MYOVIEW 30ML | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-002 | Jul 7, 2005 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MYOVIEW 30ML
When does loss-of-exclusivity occur for MYOVIEW 30ML?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
China
Patent: 1861170
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 90484
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 49203
Estimated Expiration: See Plans and Pricing
Japan
Patent: 64328
Estimated Expiration: See Plans and Pricing
Patent: 10539222
Estimated Expiration: See Plans and Pricing
Spain
Patent: 62441
Estimated Expiration: See Plans and Pricing
United Kingdom
Patent: 18386
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering MYOVIEW 30ML around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 171416 | See Plans and Pricing | |
| China | 1031828 | See Plans and Pricing | |
| China | 101861170 | Improved radiopharmaceutical composition | See Plans and Pricing |
| China | 1022633 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MYOVIEW 30ML
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 300736 | Netherlands | See Plans and Pricing | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
